{"disease":{"id":"low-dose-radiotherapy","name":"low dose radiotherapy"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Small-cell lung cancer (olaparib + low-dose radiotherapy)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT07040956","title":"A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06714708","title":"Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":86,"lead_sponsor_name":"Anhui Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT05543070","title":"Low-dose Radiotherapy in iNHL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":73,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05615142","title":"Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT06331585","title":"Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Hetian District People's Hospital","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}